Chairman, President & CEO, Abbott Laboratories
Search every verified Robert Ford interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On Abbott's Q4 2024 earnings call, Robert Ford described the company's finish to 2024 as "really strong," citing over 10% organic sales growth and 13% EPS growth. He discussed the company's pipeline, including the Volt catheter and PFA technology, and said he felt "good about the business." Ford also commented on tax policy, stating that "most companies pay their fair share" and criticized the Pillar Two legislation as adding $200 million in expense, two-thirds of which he said would be paid to overseas countries. In Q1 2026, Ford said the integration of Exact Sciences was "going very well" and expressed confidence in an acceleration of growth in the second half of the year. He described the CGM market as having "70 to 80 million people" who should be on a CGM globally, with the market currently at "10 to 12" million, and said he was "very bullish" on the market. On the Q2 2026 call, Ford reiterated his bullish outlook on the CGM market, stating there are "75 to 80 million people around the world that could realistically be on a CGM" with only 15 million so far. He also said the company's gross margin expansion efforts allowed it to raise full-year EPS guidance.
Abbott Laboratories Q2 2026 Earnings Conference Call. Twitter - https://x.com/i101yt If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders | AGM | Annual General Meeting If you want us to remove your compan…
07/16/2026 Q&A: 13:55 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Meniere…
04/16/2026 Q&A: 13:48 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Meniere…
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
The Boston College Chief Executives Club welcomed Robert B. Ford, the Chairman & CEO of Abbott, to engage in a fireside chat ...
04/16/2025 Q&A: 15:37 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Menie…
10/16/2024 Q&A: 13:33 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health ...
04/17/2024 Q&A: 15:41 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Meniere's disease and vesti…
01/24/2024 Q&A: 16:03 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothy…
Sign in to search the full transcript archive, filter by topic, and access every quote from Robert Ford.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans